NASDAQ:ZFGN - Zafgen Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$10.20
▲ +0.2 (2.00%)
Get New Zafgen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZFGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZFGN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Zafgen in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $10.20.

This chart shows the closing price for ZFGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Zafgen. This rating has held steady since December 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
2/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/23/2019WedbushReiterated RatingHold$0.78N/A
11/14/2019WedbushReiterated RatingHold$0.78Low
9/6/2019Roth CapitalDowngradeBuy ➝ NeutralLow
9/6/2019WedbushDowngradeOutperform ➝ Neutral$6.00 ➝ $0.78High
9/5/2019JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
8/12/2019WedbushReiterated RatingOutperform$6.00Medium
5/30/2019WedbushReiterated RatingBuy$6.00Medium
5/30/2019CowenReiterated RatingHoldMedium
5/30/2019Piper Jaffray CompaniesLower Price TargetOverweight ➝ Hold$6.00 ➝ $5.00Medium
5/16/2019WedbushReiterated RatingBuy$6.00Medium
4/26/2019Roth CapitalInitiated CoverageBuy ➝ Buy$8.00High
3/12/2019JMP SecuritiesBoost Price TargetOutperform ➝ Hold$8.00 ➝ $17.00High
3/11/2019Piper Jaffray CompaniesLower Price TargetOverweight ➝ Hold$18.00 ➝ $6.00High
2/7/2019SVB LeerinkUpgradeMarket Perform ➝ OutperformHigh
1/17/2019CowenReiterated RatingHoldHigh
8/2/2018WedbushInitiated CoverageOutperform$14.00High
7/3/2018Piper Jaffray CompaniesInitiated CoverageOverweight$18.00High
6/25/2018CowenReiterated RatingNeutral ➝ HoldHigh
5/9/2018CowenReiterated RatingHoldLow
3/7/2018JMP SecuritiesReiterated RatingOutperform$11.00 ➝ $20.00High
4/20/2017Roth CapitalInitiated CoverageBuy ➝ Buy$9.00High
3/10/2017CowenReiterated RatingHoldN/A
3/7/2017(FBRC)Reiterated RatingMarketperformLow
9/20/2016(FBRC)Reiterated RatingHoldN/A
8/25/2016CowenReiterated RatingBuy$60.00N/A
(Data available from 8/5/2016 forward)
Zafgen logo
Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $10.20
Low: $9.99
High: $11.06

50 Day Range

MA: $18.47
Low: $0.99
High: $25.06

52 Week Range

Now: $10.20
Low: $0.62
High: $2.76

Volume

91,695 shs

Average Volume

360,199 shs

Market Capitalization

$382.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Zafgen?

The following Wall Street research analysts have issued stock ratings on Zafgen in the last twelve months:
View the latest analyst ratings for ZFGN.

What is the current price target for Zafgen?

0 Wall Street analysts have set twelve-month price targets for Zafgen in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Zafgen in the next year.
View the latest price targets for ZFGN.

What is the current consensus analyst rating for Zafgen?

Zafgen currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ZFGN.

What other companies compete with Zafgen?

How do I contact Zafgen's investor relations team?

Zafgen's physical mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company's listed phone number is 617-622-4003 and its investor relations email address is [email protected] The official website for Zafgen is www.zafgen.com.